🇺🇸 FDA
Pipeline program

Almonertinib 110 MG

NCC2380

Phase 2 small_molecule active

Quick answer

Almonertinib 110 MG for Rare Tumor is a Phase 2 program (small_molecule) at Chinese University of Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Chinese University of Hong Kong
Indication
Rare Tumor
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials